Add this topic to your myFT Digest for news straight to your inbox
Cost of two-in-one bottle surges even though drugs can be bought separately for $36
Cautious sentiment risks cutting off funding for smaller biotechs
Mike Pearson upended big pharma with Valeant and investors applauded, but critics say it risks collapse under a huge debt pile
Department stores reel after veteran group cuts profit forecast
Chief says target’s largest shareholders support a deal
International Edition